Effects of sex and APOE ε4 genotype on brain mitochondrial high-energy phosphates in midlife individuals at risk for Alzheimer's disease: A 31Phosphorus MR spectroscopy study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
09
2022
accepted:
19
01
2023
entrez:
14
2
2023
pubmed:
15
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
Age, female sex, and APOE epsilon 4 (APOE4) genotype are the three greatest risk factors for late-onset Alzheimer's disease (AD). The convergence of these risks creates a hypometabolic AD-risk profile unique to women, which may help explain their higher lifetime risk of AD. Less is known about APOE4 effects in men, although APOE4 positive men also experience an increased AD risk. This study uses 31Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) to examine effects of sex and APOE4 status on brain high-energy phosphates [adenosine triphosphate (ATP), phosphocreatine (PCr), inorganic phosphate (Pi)] and membrane phospholipids [phosphomonoesters (PME), phosphodiesters (PDE)] in 209 cognitively normal individuals at risk for AD, ages 40-65, 80% female, 46% APOE4 carriers (APOE4+). Women exhibited lower PCr/ATP and PCr/Pi levels than men in AD-vulnerable regions, including frontal, posterior cingulate, lateral and medial temporal cortex (multi-variable adjusted p≤0.037). The APOE4+ group exhibited lower PCr/ATP and PCr/Pi in frontal regions as compared to non-carriers (APOE4-) (multi-variable adjusted p≤0.005). Sex by APOE4 status interactions were observed in frontal regions (multi-variable adjusted p≤0.046), where both female groups and APOE4+ men exhibited lower PCr/ATP and PCr/Pi than APOE4- men. Among men, APOE4 homozygotes exhibited lower frontal PCr/ATP than heterozygotes and non-carriers. There were no significant effects of sex or APOE4 status on Pi/ATP and PME/PDE measures. Among midlife individuals at risk for AD, women exhibit lower PCr/ATP (e.g. higher ATP utilization) and lower PCr/Pi (e.g. higher energy demand) than age-controlled men, independent of APOE4 status. However, a double dose of APOE4 allele shifted men's brains to a similar metabolic range as women's brains. Examination of brain metabolic heterogeneity can support identification of AD-specific pathways within at-risk subgroups, further advancing both preventive and precision medicine for AD.
Identifiants
pubmed: 36787293
doi: 10.1371/journal.pone.0281302
pii: PONE-D-22-26091
pmc: PMC9928085
doi:
Substances chimiques
Apolipoprotein E4
0
Phosphates
0
Organophosphates
0
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0281302Subventions
Organisme : NIA NIH HHS
ID : P01 AG026572
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Informations de copyright
Copyright: © 2023 Jett et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Radiology. 1992 Jun;183(3):695-9
pubmed: 1584923
J Neuroradiol. 2022 Sep;49(5):370-379
pubmed: 34871672
Nat Rev Endocrinol. 2015 Jul;11(7):393-405
pubmed: 26007613
Ann N Y Acad Sci. 2008 Dec;1147:206-20
pubmed: 19076443
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14670-5
pubmed: 19667196
Neuron. 2009 Aug 13;63(3):287-303
pubmed: 19679070
Nat Rev Neurol. 2018 Aug;14(8):457-469
pubmed: 29985474
NMR Biomed. 1993 Jan-Feb;6(1):53-7
pubmed: 8457427
Alzheimers Dement. 2018 Sep;14(9):1193-1203
pubmed: 29803541
Ann Neurol. 2014 Apr;75(4):563-73
pubmed: 24623176
Arch Neurol. 2005 Jun;62(6):953-7
pubmed: 15956166
J Alzheimers Dis. 2012;31 Suppl 3:S75-86
pubmed: 22426021
JAMA. 1997 Oct 22-29;278(16):1349-56
pubmed: 9343467
Neuroimage. 2000 Jun;11(6 Pt 1):805-21
pubmed: 10860804
PLoS One. 2018 Dec 12;13(12):e0207885
pubmed: 30540774
Magn Reson Med. 2007 Jan;57(1):103-14
pubmed: 17191226
Sci Rep. 2020 May 22;10(1):8528
pubmed: 32444841
Ann N Y Acad Sci. 2004 Jun;1019:24-8
pubmed: 15246987
J Nucl Med. 2019 Jun;60(6):837-843
pubmed: 30389825
Mol Cell Neurosci. 2007 Nov;36(3):313-31
pubmed: 17822919
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Neurochem Res. 2001 Jul;26(7):771-82
pubmed: 11565608
Eur Psychiatry. 1997;12(3):140-8
pubmed: 19698521
JAMA Neurol. 2017 Oct 1;74(10):1178-1189
pubmed: 28846757
J Neurosci. 2012 Jun 13;32(24):8254-62
pubmed: 22699906
Front Neurosci. 2021 Apr 06;15:641739
pubmed: 33889067
Ann Neurol. 1995 Aug;38(2):194-201
pubmed: 7654066
J Alzheimers Dis. 2010;20 Suppl 2:S591-607
pubmed: 20463407
NMR Biomed. 2020 Feb 10;:e4246
pubmed: 32037688
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9
pubmed: 11248079
Lancet. 1993 Sep 18;342(8873):737
pubmed: 8103832
Neurology. 2021 Dec 7;97(23):e2328-e2339
pubmed: 34732544
Alzheimers Dement. 2021 Mar;17(3):327-406
pubmed: 33756057
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3988-93
pubmed: 19234118
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18670-5
pubmed: 20937894
PLoS One. 2020 Jan 9;15(1):e0225392
pubmed: 31917799
J Alzheimers Dis. 2018;62(3):1403-1416
pubmed: 29036828
JAMA Neurol. 2018 Aug 1;75(8):989-998
pubmed: 29801024
Parkinsonism Relat Disord. 2014 May;20(5):545-8
pubmed: 24593902
Nat Rev Neurol. 2013 Jan;9(1):54-8
pubmed: 23183885
Neurology. 2007 May 8;68(19):1603-6
pubmed: 17485647
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
JAMA Neurol. 2013 Mar 1;70(3):320-5
pubmed: 23599929
Nature. 2006 Oct 19;443(7113):787-95
pubmed: 17051205
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8299-302
pubmed: 15932949
Alzheimers Dement (Amst). 2020 Nov 20;12(1):e12121
pubmed: 33251322
Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510
pubmed: 15747152
Biol Psychiatry. 2010 Nov 15;68(10):879-84
pubmed: 20598287
Brain. 2021 Nov 29;144(10):3201-3211
pubmed: 33876815
Int J Mol Sci. 2022 Jun 30;23(13):
pubmed: 35806267
Neurobiol Aging. 2015 Jul;36(7):2282-2295
pubmed: 25921624
Neurology. 2017 Sep 26;89(13):1382-1390
pubmed: 28855400
PLoS One. 2013 Nov 11;8(11):e79977
pubmed: 24244584
Front Aging Neurosci. 2016 Oct 04;8:232
pubmed: 27757081
Neurobiol Aging. 2012 Apr;33(4):720-731.e4
pubmed: 20619505
Nat Rev Neurosci. 2006 Apr;7(4):278-94
pubmed: 16552414
Front Aging Neurosci. 2019 Nov 15;11:315
pubmed: 31803046
JAMA. 1994 May 4;271(17):1316-7
pubmed: 8158809
J Alzheimers Dis. 2018;62(1):115-131
pubmed: 29439356
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1671-5
pubmed: 1311847
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6409-14
pubmed: 18443293
J Alzheimers Dis. 2017;56(3):947-957
pubmed: 28106548
PLoS One. 2011;6(7):e21788
pubmed: 21747957
Nat Commun. 2020 Mar 2;11(1):1148
pubmed: 32123170
Neuroimage Clin. 2018 Feb 28;18:254-261
pubmed: 29876246
Sci Rep. 2021 Jun 9;11(1):10867
pubmed: 34108509
Neurology. 2001 Jul 10;57(1):89-95
pubmed: 11445633
Ageing Res Rev. 2021 Dec;72:101503
pubmed: 34751136
J Steroid Biochem Mol Biol. 2016 Jun;160:134-47
pubmed: 26969397
PLoS One. 2018 Feb 15;13(2):e0193314
pubmed: 29447296
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9
pubmed: 14688411
Neurology. 2020 Jul 14;95(2):e166-e178
pubmed: 32580974
Neurobiol Aging. 2020 Sep;93:69-77
pubmed: 32464432
J Neurosci. 2001 Jun 15;21(12):4183-7
pubmed: 11404403
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573
NMR Biomed. 2010 Apr;23(3):242-50
pubmed: 19908224
Neurobiol Aging. 1994 Jan-Feb;15(1):117-32
pubmed: 8159258